SSY Group Ltd
HKEX:2005
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Freshpet Inc
NASDAQ:FRPT
|
US |
|
SOM Distilleries and Breweries Ltd
NSE:SDBL
|
IN |
|
B
|
Bio-Works Technologies AB
STO:BIOWKS
|
SE |
|
Nanjing Hicin Pharmaceutical Co Ltd
SZSE:300584
|
CN |
|
Shanghai Guao Electronic Technology Co Ltd
SZSE:300551
|
CN |
SSY Group Ltd
Total Current Assets
SSY Group Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SSY Group Ltd
HKEX:2005
|
Total Current Assets
HK$5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
12%
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Total Current Assets
$4.9m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
66%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Total Current Assets
HK$8.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
13%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Total Current Assets
¥34.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Total Current Assets
HK$201.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Total Current Assets
$1.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
24%
|
CAGR 10-Years
33%
|
|
SSY Group Ltd
Glance View
SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.
See Also
What is SSY Group Ltd's Total Current Assets?
Total Current Assets
5B
HKD
Based on the financial report for Dec 31, 2025, SSY Group Ltd's Total Current Assets amounts to 5B HKD.
What is SSY Group Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
12%
Over the last year, the Total Current Assets growth was -2%.